AI in Medicine News — 2026-09-25 (Fri)

Latest news on AI and cancer treatment

Overview

Movement was concentrated in the diagnostic/imaging field (breast cancer screening, prediction of complications related to lung treatment, esophageal cancer screening, radiology AI utilization). In the drug discovery field, while there were topics about the preclinical and exploration stages, such as the expansion of AbbVie's partnership, there were no headlines about new approvals or designations by regulatory authorities (FDA, EMA, PMDA).

Breast cancer

- An AI model that integrates multiple modalities (ultrasound + digital breast tomosynthesis) was reported to improve specificity in breast cancer screening triage (News-Medical, EurekAlert!). The target population and stage of evidence (preclinical/single-center retrospective/randomized controlled trial, etc.) are unclear from the headline. - There was a report that Israeli researchers are promoting the use of AI for cancer treatment and diagnosis (Jewish Telegraphic Agency). The specific method and results are unknown.

lung cancer

- It has been reported that an AI model using regular CT images may be able to identify patients at risk of severe lung inflammation associated with treatment (therapy-induced pneumonitis) (Newswise). The target and evidence stage are unclear from the headline. - There was a report that AI evaluates cardiovascular risk using regular CT images (Cardiovascular Business). The headline does not clearly indicate a direct relationship with cancer types. - It was reported that an AI model for esophageal cancer screening has been developed in China (СБ Беларусь). Although the topic is esophageal cancer rather than lung cancer, it was added because it was classified in this article group. Detailed accuracy and stage are unknown.

Malignant brain tumor

It was reported in 2 Minute Medicine that large-scale language models (LLMs) were able to generate accurate content in the production of research manuscripts, but that more complex analyzes required human supervision. Please note that this is a report on research writing support, not on brain tumor imaging diagnosis or treatment planning itself.

Leukemia/lymphoma

No applicable information

Colon cancer/digestive organ

It was reported that BigHat has raised $75 million as AI-designed biologics enter the clinic (FirstWord). The target disease and clinical stage (phase, etc.) are unclear from the headline. It is not specified whether the content is specific to colorectal cancer.

Rare cancer

There was a report that Ambitious Bio is creating a proteomics (protein expression) dataset for research and drug discovery using AI (GenomeWeb). Although the classification in the headline states that the disease falls under the category of "adenoid cystic carcinoma," the details of the target cancer type and stage are unclear in the text of the article.

Diagnosis/Pathology/Image

- It was reported that AI outperformed standard methods in predicting organ failure in patients with acute pancreatitis (Radiology Business). The evidence stage is unclear from the headline. - Announced that Leica Biosystems has added Tempus' oncology AI tools to the Aperio AI Store (clpmag.com). This is a product integration announcement, and there is no mention of clinical results. - There was an editorial article about the rise of "AI-native radiology treatment" (STAT). - There was a report that a radiology startup is combining medical practice and AI development (UA.NEWS, STAT). - There was a report that cancer-related questions were the top questions asked to AI doctors in nine countries (KTEN).

Treatment selection/drug discovery

- It was announced that AbbVie will partner with Iambic to accelerate AI drug discovery in the fields of immunology, neuroscience, and oncology (Pulse 2.0). The stage appears to be preclinical/exploratory, but the heading does not specify this. - AbbVie is reportedly expanding AI drug discovery through new partnerships and industry initiatives (simplywall.st). - There was an article discussing whether AI can actually save lives (Vox). It does not report specific clinical trial or product results. - There was an article (36kr.com) discussing the main limitations and practical challenges of AlphaFold's inability to solve the challenges of AI drug discovery. The content is critical and analytical, and does not contain new empirical data.

Regulations/Approval

No applicable information

Clinical trial implementation status

Information regarding the specific trial name, target cancer type, phase, and registration status from ClinicalTrials.gov was not included in the input data. We do not make assumptions about the number or status of cases.

Japanese movements

There was an article called "Artificial Intelligence in Genomics Manufacturer Ranking" (pando.life). The specific details of the use of AI in cancer treatment in Japan are unclear from the headline.

Remarks from VIPs

No relevant information (The list of important people being tracked is also blank, so statements are not linked)

Latest news on AI and rare and incurable diseases

Overview

Only one headline was collected this time, and it was about genetic analysis and genome-related funding. No headlines indicating specific developments regarding diagnostics, therapeutic drugs, or systems could be confirmed.

Diagnosis of rare diseases

No applicable information

Gene analysis/genome

Codebreaker Labs has reportedly raised $4.5 million in seed funding to build a data infrastructure for genome analysis AI (source: Dealroom). The headline does not indicate specific verification results for the target disease or technology (mutation interpretation accuracy, diagnostic rate, etc.) and is limited to information at the funding stage. A direct relationship with rare and intractable diseases cannot be confirmed from the headline.

Development of therapeutic drugs

No applicable information

Nerve/muscular diseases

No applicable information

Immunology/Collagen disease

No applicable information

Rare metabolic/endocrine diseases

No applicable information

System/Patient Support

No applicable information

Japanese movements

No applicable information

Remarks from VIPs

No applicable information

Latest news on AI and cancer treatment

Overview

Mainly reports on the use of AI in the field of image diagnosis (CT/pathological images). In the case of lung cancer, research on predicting the risk of pneumonia associated with immunotherapy from CT images has been reported in multiple media. Although there has been movement in drug discovery and medical treatment infrastructure (EHR integration, molecular exploration), there is little primary information showing the specific progress of approvals and clinical trials.

Breast cancer

No relevant information (the headline "AI will change the way you choose snacks" is food industry news about Conagra and has nothing to do with breast cancer).

lung cancer

- A study conducted by MD Anderson Cancer Center in the US has reported that AI can analyze routinely taken CT images to identify patients at high risk of severe treatment-induced pneumonitis associated with immunotherapy. The same content was also reported on Bioengineer.org and News-Medical. The stage of development and validation (preclinical, single-center retrospective, prospective study, etc.) cannot be determined from the headline. - The NYT editorial, ``AI has made me better doctors, but made me worse medical students,'' is a general medical education theory that is not limited to lung cancer, and does not include findings regarding cancer types.

Malignant brain tumor

No relevant information (“AI improves brain aneurysm detection by 39%” relates to brain aneurysms = vascular disease, which is different from brain tumors).

Leukemia/lymphoma

- Dr. Encinas Mayoral comments on the benefits of the AI-designed BCMA/FcRL5-targeting TRiTE (T-cell inducing bispecific molecule) in OncLive regarding multiple myeloma (a type of blood cancer). The development stage (preclinical/clinical) is unclear from the headline.

Colon cancer/digestive organ

- Regarding pancreatic cancer (gastrointestinal cancer), a report using AI modeling has identified a hidden molecular switch that can activate "cold" tumors (tumors with poor immune response) (Bioengineer.org). The details of the research stage (pre-clinical model, etc.) are unclear from the headline.

Rare cancer

No applicable information.

Diagnosis/Pathology/Image

- Announcement that Leica Biosystems will integrate Tempus AI into the Aperio AI Store. This is a product integration related to a digital pathology platform across cancer types, and performance data is not listed in the headline. - Published a review paper on biomarker discovery using AI (possibility of application to diagnosis and treatment) in Nature magazine. This is a general article, and individual accuracy data is unclear from the headline. - (Reference) "AI improves cerebral aneurysm detection by 39%" is said to be a study based on actual clinical data, but it is not the main subject of this report because it targets cerebrovascular disease rather than cancer.

Treatment selection/drug discovery

- AI model that predicts immunotherapy-related pneumonia risk from CT (News-Medical, same study as lung cancer item). - Medium editorial (by Sergei Polevikov) "AI 0: Cancer 1" is a blog-style article that discusses the results of testing five cutting-edge AI models on cancer-related tasks. It needs to be treated as an individual's analysis and opinion, rather than peer-reviewed research. - Oracle launches AI-powered electronic health record (EHR) for oncology. Product announcements rather than clinical efficacy data. - Bioengineer.org published an article explaining the trend, titled ``AI from a laboratory rarity to a fundamental technology for tumor treatment.'' - The coverage of AbbVie's molecular search AI (search using 6,000 characteristics) relates to the early stage of drug discovery (candidate molecule search) and does not include information on the clinical stage.

Regulations/Approval

No relevant information (The Investing.com article mentions "Japan approval," but the specific product name and approval classification are not listed in the headline, and as the content deals with stock price trends, it is outside the scope of this report.)

Clinical trial implementation status

No applicable information (The information provided this time does not include data on the specific trial name, target cancer type, phase, and registration status from ClinicalTrials.gov).

Japanese movements

- A press release from Report Ocean Co., Ltd. announced that the diagnostic equipment market is predicted to reach US$73.5 billion in 2035 (CAGR 4.8%). The increase in chronic diseases and the spread of high-precision diagnostic equipment through AI and digitalization are cited as growth factors, but these are forecasts for the entire market, not figures specific to cancer diagnosis. - There have been reports of a 24-hour AI chat service called "VetCall" for veterinary hospitals (which responds to inquiries during closed hours), but this is a service in the field of veterinary medicine and has nothing to do with human cancer treatment. - The Investing.com article (with reference to diagnostic-related stocks selected by an AI model and approval in Japan) is about stock prices and investment, so we cannot confirm any concrete support for it as regulatory information.

Remarks from VIPs

- Dr. Encinas Mayoral (Title details not listed in headline, OncLive interview): Mentioned the benefits of AI-designed BCMA/FcRL5-targeted TRiTE in the treatment of multiple myeloma. - Sergei Polevikov (Medium contributor): Commentary on the results of testing five cutting-edge AI models on cancer-related tasks (personal blog post before peer review).

Latest news on AI and rare and incurable diseases

Overview

Only two headlines were provided, and it was not possible to confirm any concrete progress regarding diagnosis, therapeutic drugs, or systems. It concerns the business trends of corn breeding and cancer genome analysis companies, and has little direct connection to the field of rare and incurable diseases.

Diagnosis of rare diseases

No applicable information.

Gene analysis/genome

There are reports that Tempus AI is expanding its whole genome sequencing business, but the headline only mentions business evaluation, and does not indicate specific clinical results such as application to rare disease diagnosis or detection rate/diagnosis rate.

Development of therapeutic drugs

No applicable information.

Nerve/muscular diseases

No applicable information.

Immunology/Collagen disease

No applicable information.

Rare metabolic/endocrine diseases

No applicable information.

System/Patient Support

No applicable information.

Japanese movements

No applicable information.

Remarks from VIPs

No applicable information.

Furthermore, ``Agriculture companies collaborate to advance climate-resilient corn using AI and gene editing'' was excluded from the analysis because it is related to the agricultural field (breeding of climate-resistant corn) and has nothing to do with rare and intractable human diseases.